Overview of Deynek

Property	Description
Active Ingredient	Paracetamol and/or Mefenamic Acid
Form	Tablet or Oral Suspension
Pharmacological Class	Analgesic, NSAID
General Purpose	Pain relief, fever reduction, anti-inflammatory action
Origin	Synthetic

What Type of Medicine is Deynek?

Deynek is the proprietary name for a pharmaceutical product classified primarily as an analgesic (pain reliever) and often as an NSAID (Non-Steroidal Anti-Inflammatory Drug). Its general therapeutic goal is to address mild to moderate pain and reduce both fever and inflammation. Deynek provides systemic relief by targeting the body's internal chemical pathways responsible for discomfort.

Unlike antibiotics, which fight bacteria, this medicine is focused purely on symptom management. Deynek is known in various global markets and is often positioned toward pediatric or family use due to the availability of its popular oral suspension form. The active components are manufactured chemically, making it a synthetic drug.

What Ingredients Does Deynek Contain?

Deynek typically contains one or both of the common pain-relieving active ingredients: Paracetamol (Acetaminophen) and/or Mefenamic Acid. It is formulated for oral administration, most commonly available as a tablet or a liquid oral suspension.

The specific formulation dictates whether it is a single-ingredient product or a combination product, offering a dual action for comprehensive symptom relief. NSAIDs like Mefenamic Acid inhibit cyclooxygenase (COX) activity, which means the medicine helps prevent the generation of those chemicals responsible for initiating pain signals.

What is the Goal of Deynek Treatment?

The primary goal of Deynek treatment is to suppress the sensation of discomfort and reduce high body temperature in patients experiencing symptomatic issues, such as muscle aches or fever. The high-level principle involves interfering with the body's production of key chemical messengers, called prostaglandins, that signal pain and promote inflammation.

By blocking these signals and aiding internal temperature regulation, Deynek provides effective symptomatic relief, making it a staple medicine for general family health issues.

Regulatory References

What side effects are possible with Deynek?

Possible Side Effects and Safety Information

Common Adverse Effects

Deynek (containing Mefenamic acid and Paracetamol/Acetaminophen) is generally well-tolerated when used as prescribed. However, like all medications, it can cause side effects. The most frequently reported adverse reactions are related to the gastrointestinal system and often include:

Nausea and vomiting
Diarrhea or constipation
Indigestion or heartburn
Stomach pain
Loss of appetite

Other common, non-gastrointestinal side effects may include dizziness, drowsiness, and headache. Taking this medication with food or milk may help reduce gastrointestinal discomfort.

Serious Warnings and Contraindications

Deynek is a combination product that should be used with caution, particularly due to the presence of Mefenamic acid, a Non-Steroidal Anti-Inflammatory Drug (NSAID), and Paracetamol. NSAIDs carry a Boxed Warning regarding the potential for serious cardiovascular and gastrointestinal risks.

System	Serious Potential Risks
Cardiovascular	Increased risk of serious adverse thrombotic events (e.g., heart attack, stroke), which can be fatal. This risk may increase with duration of use and in those with pre-existing heart disease.
Gastrointestinal	Increased risk of serious events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. Risk is higher in the elderly and those with a history of GI issues.
Hepatic	Liver toxicity and failure, especially with prolonged use or doses exceeding recommended amounts (due to Paracetamol).
Renal	Kidney damage, particularly with long-term use.

Do not use Deynek if you have a known allergy to Mefenamic acid, Paracetamol, or other NSAIDs (e.g., aspirin), or if you have a history of severe heart, liver, or kidney failure, or active gastrointestinal bleeding or peptic ulcers. Consult a healthcare professional immediately if you experience chest pain, sudden weakness, bloody or black stools, or yellowing of the skin or eyes.

Overdose and Emergency Response

The regulatory documentation for Deynek, which may contain Paracetamol and/or Mefenamic Acid, details specific overdose manifestations and required emergency actions.

Documented Manifestations and Severe Outcomes

Overdose commonly presents with initial symptoms of nausea, vomiting, pallor, and abdominal pain. Regulatory texts note that later presentations can involve signs of hepatic dysfunction, jaundice, and metabolic acidosis. Severe outcomes documented include delayed hepatic failure, acute renal failure, and complications such as encephalopathy or haemorrhage. Overdose involving Mefenamic Acid is associated with acute convulsions, seizures, and altered mental status.

Required Emergency Actions

It is explicitly stated by regulatory bodies that immediate medical advice must be sought and patients require an urgent referral to a hospital, even if the patient feels well initially. This is mandatory due to the documented potential for serious, delayed, and life-threatening complications. Increased risk of toxicity is noted in individuals with chronic alcoholism or severe hepatic impairment.

Management and Monitoring

Treatment is strictly symptomatic and supportive. For the Paracetamol component, treatment with N-acetylcysteine may be required, while no specific antidote is known for Mefenamic Acid. Official guidelines mandate laboratory monitoring, including measuring plasma concentration at a minimum of four hours post-ingestion and continuously tracking markers like INR and liver enzymes.

Therapeutic Uses of Deynek

Deynek is applied across domains where additional symptomatic support is needed, primarily focusing on managing the intensity of common, disruptive symptoms. This focus on pain, inflammation, and fever is associated with the medication’s core therapeutic domains. It is generally used across domains where short-term symptomatic assistance is appropriate for common ailments and minor injuries.

Managing Acute Pain and Discomfort

The medication is commonly used to help with symptom clusters that may appear suddenly in conditions presenting with acute episodes. The primary uses include easing discomfort from headache, dental pain, muscle aches, and menstrual cramping (dysmenorrhea), as well as controlling elevated body temperature associated with seasonal illnesses. Deynek provides support that helps ease the overall symptom burden of mild to moderate pain and may help reduce the interference of symptoms with daily activities.

“The core function is to offer supportive relief when symptoms create noticeable physiological strain, assisting patients in maintaining functional stability.”

Easing Systemic and Cyclical Symptoms

Deynek is applied in clinical settings that involve acute or unstable symptom patterns, such as during episodes of influenza or specific cyclical conditions like dysmenorrhea. By helping to address pronounced symptoms like high body temperature and associated malaise, the medication supports the patient during difficult episodes by easing distress and may offer supportive relief when symptoms interfere with routine activities.

Quick Fact: Relief for Mild to Moderate Pain and Fever

Eligibility and Restrictions for Use

Who Can and Cannot Use Deynek?

The official eligibility for Deynek (Paracetamol and/or Mefenamic Acid) is defined by mandatory population exclusions and restrictions documented in regulatory labeling.

Contraindicated Populations (Must Not Use)

Use is strictly contraindicated for individuals with a known hypersensitivity to either active ingredient or a history of allergic-type reactions, such as asthma or urticaria, to aspirin or other NSAIDs. Absolute prohibitions also apply to patients with severe hepatic, renal, or heart failure (NYHA Class III-IV), active gastrointestinal ulceration, or prior GI bleeding. The medicine is also contraindicated for the treatment of peri-operative pain in the setting of CABG surgery and during the third trimester of pregnancy.

Restricted Use and Limitations

Age Restrictions: Efficacy and safety for pain relief are not established in children below 14 years of age. Elderly patients are classified for cautionary use. Organ Function: Patients with non-severe hepatic impairment or severe renal impairment require caution. Reproductive Status: The medicine is not recommended for women attempting to conceive due to potential impairment of fertility, and caution is advised during the first two trimesters of pregnancy and while breastfeeding.

What should I know about interactions with other medicines?

Deynek’s interaction profile is structured around the properties of its active components (Paracetamol and/or Mefenamic Acid).

Official Interaction Statements

The Mefenamic Acid component, classified as an NSAID, is a substrate of the CYP2C9 enzyme, and its use is contraindicated in the setting of peri-operative pain following CABG surgery. Co-administration with oral anticoagulants (e.g., Warfarin) is a pharmacodynamic interaction that results in an officially documented increased risk of bleeding. Similarly, co-use with other NSAIDs, corticosteroids, or SSRIs is associated with an elevated risk of serious gastrointestinal events.

Exposure and Efficacy Modification

Mefenamic Acid may reduce the antihypertensive activities of specific blood pressure medications, including ACE Inhibitors and ARBs, an officially noted effect. Regulatory documents also note pharmacokinetic exposure modification: co-administration with magnesium-containing Antacids significantly increases the rate and extent of Mefenamic Acid absorption. Furthermore, regulatory documents require monitoring of serum levels for substances such as Lithium, Digoxin, and Methotrexate when co-administered, as their plasma concentrations may increase due to reduced clearance.

Substance and Population Notes

For the Paracetamol component, the FDA label explicitly links daily ingestion of three or more alcoholic drinks with a higher risk of severe liver damage. Population-specific notes advise that elderly patients are at greater risk for serious gastrointestinal adverse events when using the Mefenamic Acid component.

Mechanism of Action

The pharmacological activity of Deynek involves distinct, complementary actions on the body's chemical messengers and central signaling systems, primarily focusing on inhibiting mediator production and modulating nociceptive transmission pathways.

Modulation of Prostaglandin Synthesis (Mefenamic Acid & Paracetamol)

This domain covers the blocking of the cyclooxygenase ( COX) enzymes by Mefenamic Acid ( COX-1/ COX-2) and Paracetamol ( CNS COX). This enzymatic inhibition restricts the production of prostaglandins ( PGs), which are lipid mediators that contribute to local physiological responses and the upward adjustment of the hypothalamic thermoregulatory set-point. By targeting this foundational synthesis step, the mechanism results in physiological consequences that include increased heat dissipation and reduced chemical sensitization of peripheral nociceptors.

Central Nervous System Nociceptive Pathway Interference (Paracetamol)

This mechanism centers on Paracetamol’s action within the brain and spinal cord, where it influences the central processing and transmission of nociceptive signals. This involves both indirect CNS COX inhibition and the metabolite-mediated modulation of key central receptors like TRPV1 (Transient Receptor Potential Vanilloid 1) and CB1 (Cannabinoid receptor type 1). These actions modulate the activity of the descending inhibitory pathways, leading to altered central processing of nociceptive signals.

Dosage and Administration Information

Administration Method

Deynek is typically administered as an intravenous infusion. This means the medication is delivered directly into a vein over a specific period of time. The procedure is performed by healthcare professionals in a clinical setting, such as a hospital or specialized infusion center.

Preparation for the Infusion

Before the infusion begins, a healthcare provider will prepare the necessary equipment and ensure the medication is at the correct temperature and concentration. The site of injection, usually on the arm or hand, will be cleaned and prepared for the insertion of the needle or catheter.

During the Procedure

Throughout the administration process, the infusion rate is monitored to ensure the medication is delivered steadily. Healthcare staff remain present to observe the process and manage the clinical environment. Patients are usually seated or lying down comfortably during this time.

Post-Infusion Observation

After the infusion is complete, there is a period of observation. This allows healthcare providers to monitor the patient's immediate response to the medication before they are cleared to leave the facility. The duration of this observation period is determined by clinical protocols and individual patient needs.

Recent Clinical Evidence

Research evidence / Overview of studies for Deynek

Evidence for Acute Pain Relief and Postoperative Pain

The research for Deynek's active components in research exploring acute pain primarily consists of short-term, single-dose Randomized Controlled Trials (RCTs) and comprehensive systematic reviews applied in studies examining patient-reported experiences. These trials were typically conducted during periods of increased symptom activity in adults experiencing post-surgical discomfort.

Studies conducted during periods of increased symptom activity reported that the Mefenamic Acid component was observed in some studies that reported measurements of short-term changes in pain intensity. These findings describe patterns observed over the initial observation window, generally restricted to four to six hours. Comparative evidence for the specific combination product (Paracetamol and Mefenamic Acid together) is limited, and follow-up durations were limited.

Evidence for Menstrual Pain (Primary Dysmenorrhea)

Evidence for managing menstrual pain is relevant in trials assessing short-term or episodic symptom patterns. Research largely used RCTs and systematic reviews to explore outcomes related to physical discomfort in women experiencing primary dysmenorrhea. Studies monitored how symptoms evolved in the observed populations, and findings indicate patterns where the Mefenamic Acid component was associated with measured changes in the severity and length of pain during menstruation.

Evidence for Fever Reduction (Antipyresis)

Research exploring temporary physiological imbalance for fever reduction has relied on comparative Randomized Controlled Trials and observational studies focusing on pediatric patients with elevated body temperature. Studies observed that both the Mefenamic Acid component and Paracetamol research reports measured reductions in body temperature in febrile children. Some trials described patterns related to the duration of the fever-reducing effect; these studies included monitoring against other active treatments, including Paracetamol.

Understanding Research Gaps and Uncertainties

While research provides context for short-term symptom changes in approved indications, several limitations apply. Long-term effects are not well characterized, as the research scenario is generally limited to assessing acute, short-term changes. For the Mefenamic Acid component, regulatory sources have noted that appropriate studies have not been performed to establish the relationship of age to the medicine's effects in children below 14 years of age for the treatment of fever, indicating that data for certain groups remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Deynek (FAQ)

Q: What's the main difference between Deynek and other drugs for the same condition?

A: Deynek is officially classified as a combination product because it contains two distinct active components: Mefenamic Acid, which is a Non-Steroidal Anti-Inflammatory Drug (NSAID), and Paracetamol (Acetaminophen). Official documents describe this combination as providing two complementary actions to address both pain and inflammation, unlike many treatments that contain only one active ingredient.

Q: How long does it usually take to feel the effect of Deynek?

A: Regulatory documents indicate that the Mefenamic Acid component typically reaches its highest level in the bloodstream approximately 2 to 4 hours after it is taken. The Paracetamol component is known to begin acting faster. Regulatory data suggests the medicine's primary component reaches peak concentrations within a few hours.

Q: Can I stop taking Deynek if my symptoms get better?

A: Official drug labels for the Mefenamic Acid component emphasize that use should be limited to the lowest effective dose for the shortest duration necessary to control symptoms. For many acute conditions, the use of the Mefenamic Acid component is often limited to a duration of one week (7 days) in clinical studies and official labeling.

Q: Are there any foods or drinks that interact with Deynek?

A: Regulatory documents explicitly caution against chronic, excessive consumption of alcohol due to the potential for increased risk of severe liver injury associated with the Paracetamol component. While there are no broad food restrictions, some official labels note that taking the Mefenamic Acid component with food may help to reduce the risk of gastrointestinal upset.

Q: Does Deynek affect blood pressure?

A: Regulatory documents include a caution regarding the NSAID component (Mefenamic Acid), noting it can lead to the onset of new hypertension (high blood pressure) or worsen pre-existing high blood pressure. Regulatory documents indicate that this may contribute to the increased incidence of cardiovascular events.

Q: Can I cut the Deynek tablet in half?

A: Official labeling describes the tablet's overall strength and form. It is important to note that official regulatory text for combination tablets does not generally provide instructions for cutting or altering the dosage form, as this practice could potentially lead to an inconsistent dose of the combined ingredients.

Q: Are there different strengths of Deynek tablets?

A: Yes, official regulatory databases show that combination products containing Mefenamic Acid and Paracetamol are available in multiple different strengths (varying milligrams of each active component) to suit different needs. The medicine is also typically available in both a tablet and an oral suspension form.

Q: Does taking Deynek with food affect how well it works?

A: Official documentation notes that Mefenamic Acid is generally absorbed well by the body. Official information suggests that the absorption of the active components is rapid, and food does not significantly impair the intended effect, although food is sometimes suggested to reduce stomach upset.

Q: Is there a generic version of Deynek available?

A: Yes, regulatory databases list generic versions of the active ingredients contained in Deynek, which are Mefenamic Acid and Paracetamol. These components are available generically under multiple brand names worldwide.

Q: Is Deynek safe for people with liver issues?

A: Official documents strictly contraindicate the use of this medicine for individuals with a history of severe hepatic failure (severe liver failure). For patients with existing or signs of non-severe liver dysfunction, regulatory documents advise caution and may require monitoring due to the potential for abnormal liver tests during therapy.

Q: How long can I stay on Deynek?

A: Regulatory guidance states that the Mefenamic Acid component is intended for short-term use, generally limited to one week (7 days) for pain relief. Official documentation emphasizes that, to minimize potential serious risks, the Mefenamic Acid component is typically used at the lowest effective dose for the shortest duration.

Q: Is Deynek a relatively new drug?

A: No, the active components of Deynek are well-established medicines. Mefenamic Acid was first approved by the FDA in the 1960s, and Paracetamol has been available even longer, indicating the components are not considered new drugs.

Q: Why is Deynek only available by prescription?

A: Regulatory classifications from multiple international agencies define Mefenamic Acid as a prescription-only medicine (POM). This classification is primarily due to the potential for serious adverse risks associated with the NSAID component, which necessitates the medicine to be used under the supervision of a healthcare professional.

Q: Can Deynek make my existing condition worse?

A: Regulatory documents caution that the NSAID component (Mefenamic Acid) is associated with warnings that it can lead to the onset of new hypertension or worsening of pre-existing hypertension. The medicine is also strictly contraindicated in patients with severe heart, kidney, or liver failure.

Q: Are there any long-term effects of using Deynek?

A: Official regulatory warnings explicitly link an increased risk of serious adverse events with a longer duration of use. These serious risks include a potential for thrombotic events (such as heart attack or stroke) and serious gastrointestinal events (like bleeding and ulceration).

Q: Is Deynek a daily medication or taken as needed?

A: Official indications describe its use for acute conditions such as mild-to-moderate pain and primary dysmenorrhea. This guidance suggests the medicine is typically taken episodically or as needed for a short duration to address symptoms, and not for long-term daily maintenance.

Q: How should I store Deynek tablets?

A: Official labeling requires the tablets be stored at temperatures not exceeding 30 ° C and that the product must be protected from light. To maintain stability, the tablets must be kept in their original package and stored safely out of the sight and reach of children.

Q: How quickly is Deynek cleared from the body?

A: Pharmacokinetic data from regulatory sources for Mefenamic Acid indicate its elimination half-life approximates 2 hours in the blood plasma. This measurement reflects the rate at which the amount of medicine is reduced by half in the body.

Q: Is Deynek safe to use before surgery?

A: The medicine is strictly contraindicated for the treatment of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery. Due to the anti-platelet effect of the NSAID component, many official warnings advise caution or avoidance before non-CABG surgery to reduce potential bleeding risk.

Q: Does Deynek require special blood tests while taking it?

A: Regulatory documents advise that the use of NSAIDs may require monitoring of renal function (kidney function). Additionally, when the medicine is co-administered with certain other drugs, monitoring of specific serum levels (such as Lithium or Digoxin) may be required.

Q: Are there different brand names for the same medicine as Deynek?

A: Yes, as the active ingredients (Mefenamic Acid and Paracetamol) are available generically, there are many different brand names worldwide for products containing one or both of these components.

Q: What are common patient misunderstandings about Deynek?

A: Official public health information often highlights key issues, such as the importance of strictly avoiding doses that exceed the maximum recommended daily amount of Paracetamol. Another common area for clarification is understanding the serious risks associated with the long-term use or high doses of the NSAID component.

Q: Is it okay to drive while taking Deynek?

A: Regulatory guidance indicates that patients should be aware that the medicine can cause side effects such as dizziness and drowsiness before operating heavy machinery or driving.

How should Deynek be stored and disposed of?

Storage Conditions and Requirements

Official labeling requires that Deynek (Paracetamol and/or Mefenamic Acid) be stored at a temperature not exceeding 30°C. Certain formulations may specify storage at or below 25°C. To maintain stability, the medicine must be protected from light, and containers, such as those for oral suspension or capsules, must be kept tightly closed against moisture. Tablets must be retained in their original package.

Child-Safety and Disposal

For safety, the product must be stored out of the sight and reach of children, as required by regulatory agencies. Disposal of unused or expired medicine must follow official guidance: the preferred method is a community drug take-back program. If no program is available, the product should be mixed with an undesirable substance and sealed in a container for disposal in the household trash; the medicine must not be flushed down the sink or toilet.

Deynek